SONN - Sonnet BioTherapeutics Holdings Inc Stock Price, Fair Value and News

1.86USD+0.09 (+5.08%)Delayed as of 01 May 2024, 02:56 pm ET

Market Summary

USD1.86+0.09

Delayedas of 01 May 2024, 02:56 pm

5.08%

SONN Stock Price

View Fullscreen

SONN RSI Chart

SONN Valuation

Market Cap

5.4M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

42.06

EV/EBITDA

-0.32

Price/Free Cashflow

-0.29

SONN Price/Sales (Trailing)

SONN Profitability

EBT Margin

-11660.99%

Return on Equity

-562.07%

Return on Assets

-270.88%

Free Cashflow Yield

-340.85%

SONN Fundamentals

SONN Revenue

Revenue (TTM)

129.2K

Rev. Growth (Yr)

-50%

Rev. Growth (Qtr)

-50%

SONN Earnings

Earnings (TTM)

-14.5M

Earnings Growth (Yr)

78.92%

Earnings Growth (Qtr)

68.22%

Breaking Down SONN Revenue

52 Week Range

0.194.80

(Low)(High)

Last 7 days

-1.1%

Last 30 days

-5.4%

Last 90 days

20.5%

Trailing 12 Months

-65.4%

How does SONN drawdown profile look like?

SONN Financial Health

Current Ratio

1.74

Debt/Equity

0.03

Debt/Cashflow

-7.11

SONN Investor Care

Shares Dilution (1Y)

233.76%

Diluted EPS (TTM)

-20.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	198.5K	173.3K	147.8K	129.2K
2022	416.8K	383.4K	349.9K	257.4K
2021	0	0	483.6K	450.2K
2020	24.4M	28.7M	0	0
2019	28.6M	28.9M	28.4M	30.9M
2018	41.6M	41.2M	40.6M	30.7M
2017	41.6M	41.4M	41.1M	41.4M
2016	37.9M	40.2M	41.9M	41.8M
2015	29.8M	32.0M	34.2M	36.4M
2014	12.2M	17.4M	25.4M	27.6M
2013	7.1M	7.1M	6.9M	8.2M
2012	3.0M	4.6M	5.9M	6.9M
2011	549.3K	858.4K	1.2M	1.5M
2010	0	447.4K	291.9K	136.3K
2009	0	0	0	603.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sonnet BioTherapeutics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 27, 2023	mohan pankaj	bought	-	-	34,375	chairman, president and ceo
Oct 27, 2023	rao raghu	bought	-	-	15,625	-
Jun 14, 2023	dexter susan	bought	7,000	0.7	10,000	chief technical officer
May 30, 2023	dyrness albert d.	bought	10,883	0.468	23,255	-
May 17, 2023	bhatt nailesh	bought	5,800	0.232	25,000	-
May 15, 2023	mohan pankaj	bought	82,866	0.223	371,600	chairman, president and ceo
Mar 15, 2023	mohan pankaj	bought	35,100	0.585	60,000	chairman, president and ceo
Feb 06, 2023	griffith donald j.	sold (taxes)	-518	1.043	-497	-
Feb 06, 2023	cross john harry iii	sold (taxes)	-2,077	1.06	-1,960	chief financial officer
Jan 07, 2023	cini john k.	back to issuer	-	-	-18,551	chief scientific officer

Which funds bought or sold SONN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	0.68	-16,280	25,623	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-270	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	51,238	51,238	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-57.04	-301	106	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	new	-	3,644	3,644	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-668	1,034	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	129	21,000	76,000	-%
Feb 12, 2024	JPMORGAN CHASE & CO	new	-	33.00	33.00	-%
Feb 12, 2024	OSAIC HOLDINGS, INC.	unchanged	-	-51.00	78.00	-%
Feb 09, 2024	CITIGROUP INC	sold off	-100	-9.00	-	-%

Are Funds Buying or Selling SONN?

Are funds buying SONN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SONN

No. of Funds

Unveiling Sonnet BioTherapeutics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	markey john	6.5%	198,300	SC 13G/A
Nov 17, 2023	markey john	7.6%	231,115	SC 13G/A
Nov 06, 2023	markey john	6.4%	195,780	SC 13G/A
Aug 07, 2023	markey john	10.7%	4,100,000	SC 13G/A
Jul 17, 2023	markey john	11.1%	3,700,000	SC 13G/A
Jul 07, 2023	markey john	9.9%	3,305,000	SC 13G/A
Jun 30, 2023	markey john	8.5%	2,830,000	SC 13G
Jun 22, 2023	ruck matthew j	6.18%	1,700,000	SC 13G/A
Jun 14, 2023	ruck matthew j	5.83%	1,603,006	SC 13G/A
Jun 14, 2023	ruck matthew j	5.83%	1,603,006	SC 13G/A

Recent SEC filings of Sonnet BioTherapeutics Holdings Inc

View All Filings

Date Filed	Form Type	Document
Mar 11, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Feb 14, 2024	8-K	Current Report
Feb 14, 2024	10-Q	Quarterly Report
Feb 01, 2024	8-K	Current Report
Jan 29, 2024	8-K	Current Report

Peers (Alternatives to Sonnet BioTherapeutics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.44	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Sonnet BioTherapeutics Holdings Inc News

Latest updates

Sonnet BioTherapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-50.0%	18,626	37,255	36,850	36,445	37,255	62,753	62,071	95,320	5,063,547	10,031,773	15,000,000	1,355,000	2,715,030	9,653,440	10,710,773	7,837,588	239,633	10,098,400	10,399,924	9,995,516	10,082,185
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	7,035,328	7,920,004	13,886,882	13,695,319	9,532,462	2,136,460	10,769,716	10,820,269	12,376,357	11,848,276
Operating Expenses	-64.3%	1,297,497	3,637,400	3,952,160	5,701,213	5,649,649	7,439,718	7,929,297	8,305,536	6,344,751	7,430,510	-	3,625,844	1,199,435	5,858,495	6,557,415	5,151,483	1,415,944	5,781,284	5,640,614	5,586,149	5,782,592
S&GA Expenses	-63.6%	653,455	1,794,765	1,542,689	1,884,569	1,903,709	2,315,790	2,280,345	1,900,263	2,078,885	2,392,208	2,484,148	1,208,374	1,060,906	1,572,774	1,012,290	1,338,881	454,534	1,092,529	1,121,666	1,193,417	-
R&D Expenses	-65.0%	644,042	1,842,635	2,409,471	3,816,644	3,745,940	5,123,929	5,648,952	6,405,273	4,265,866	5,038,302	2,455,822	1,302,515	1,408,148	-	391,914	-	-	-	-	-	-
EBITDA Margin	100.0%	-	-113	-97.11	-84.78	-65.39	-48.09	-43.90	-40.38	-37.38	-34.80	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-3,798	162,988	222,899	162,845	-11,855	208,223	654,274	630,223	629,858	635,081	646,249
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-3,676	12,513	4,803	5,829	50,581	78,137	-206,366	-236,798	-336,197	-813,827
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-1,796,202	-7,823,008	-4,286,482	-3,329,837	-1,922,528	-2,485,933	-1,524,978	-1,042,598	-3,018,036	-2,349,405
EBT Margin	100.0%	-	-116	-99.45	-86.82	-66.96	-49.25	-44.96	-41.35	-38.28	-35.64	-	-	-	-	-	-	-	-	-	-	-
Net Income	68.2%	-1,168,509	-3,676,739	-3,946,742	-5,667,071	-5,542,142	-7,435,341	-7,877,020	-8,208,499	-6,200,981	-6,952,073	-11,779,050	-2,496,747	-2,469,054	-4,291,285	-1,416,059	-283,680	-292,047	-1,318,612	-805,805	-2,681,839	-
Net Income Margin	12.2%	-111	-127	-130	-133	-112	-84.93	-76.27	-65.93	-56.21	-51.66	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	32.2%	-3,091,737	-4,559,113	-6,172,025	-4,695,534	-5,915,170	-6,247,934	-7,824,682	-5,608,563	-8,092,349	-5,938,127	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.7%	5,338	5,429	10,035	13,311	4,943	5,830	7,490	15,046	20,741	28,994	7,176	7,626	3,033	7,994	3,881	31,319	31,533	38,478	45,424	48,086	29,793
Current Assets	-2.4%	4,624	4,738	9,633	13,046	4,598	5,414	7,169	14,916	20,584	28,812	6,972	7,398	2,699	7,638	3,502	1,818	1,170	40.00	1,769	1,703	1,344
Cash Equivalents	32.9%	3,021	2,274	7,000	11,400	1,700	3,053	5,225	13,636	19,400	27,622	6,038	6,739	2,348	7,350	3,107	549	501	36.00	579	562	524
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	272	287	354	421	425	335
Net PPE	-9.6%	30.00	33.00	37.00	40.00	43.00	46.00	49.00	53.00	56.00	59.00	59.00	62.00	65.00	68.00	71.00	5,325	5,630	8,160	9,012	10,157	9,756
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,513	8,568	10,499	11,275	11,313	10,564
Liabilities	-51.1%	2,765	5,655	6,616	7,943	8,480	8,369	6,725	6,513	4,350	6,734	5,807	5,603	5,520	4,974	3,501	34,274	34,685	36,592	38,500	41,123	21,536
Current Liabilities	-52.0%	2,654	5,525	6,466	7,774	8,293	8,165	6,505	6,513	4,345	6,703	5,752	5,398	5,292	4,724	3,230	18,205	18,095	2,885	19,880	21,975	13,025
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,000
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,348	6,631	6,682	6,620	6,772	3,663
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,000
Shareholder's Equity	1238.4%	2,572	-225	3,418	5,369	-3,537	-2,538	764	8,533	16,391	22,260	1,369	2,022	-	3,020	380	-	-	5,133	6,924	6,963	8,258
Retained Earnings	-1.1%	-111,412	-110,243	-106,567	-102,620	-96,953	-91,411	-83,975	-76,098	-67,890	-61,689	-54,737	-48,621	-42,582	-36,705	-29,184	-77,343	-75,068	-12,440	-62,270	-59,025	-57,124
Additional Paid-In Capital	3.6%	113,984	110,018	109,982	107,987	93,415	88,872	84,734	84,626	84,275	83,949	56,103	50,642	40,094	39,724	29,564	73,471	71,506	9,594	71,210	65,126	64,757
Shares Outstanding	75.4%	3,070	1,750	1,745	932	314	252	197	196	196	196	73.00	61.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	585	456	485	910	1,027	827
Float	-	-	-	-	7,300	-	-	-	22,100	-	-	-	45,019	-	-	-	5,713	-	-	4,300	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	32.2%	-3,091	-4,559	-6,172	-4,695	-5,915	-6,247	-7,824	-5,608	-8,092	-5,938	-5,844	-5,787	-4,981	-5,542	-6,439	-1,905	-1,807	-1,770	293	-646	-1,378
Share Based Compensation	0.0%	50.00	50.00	50.00	57.00	92.00	86.00	108	351	332	318	318	370	370	-	-	28.00	9.00	7.00	10.00	101	-
Cashflow From Investing	100.0%	-	-170	-12.00	-	-	62.00	-586	-165	-120	-	-	-	-	-	-22.82	-19.71	-21.75	2,930	-183	-18.79	-322
Cashflow From Financing	21789.8%	3,839	-17.70	1,815	14,646	4,563	-	-	-	-	27,526	5,144	10,178	-20.12	9,786	8,947	2,007	2,684	244	-92.95	597	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SONN Income Statement

2023-12-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 18,626	$ 37,255
Operating expenses:
Research and development	644,042	3,745,940
General and administrative	653,455	1,903,709
Total operating expenses	1,297,497	5,649,649
Loss from operations	(1,278,871)	(5,612,394)
Foreign exchange gain	110,362	70,252
Net loss	$ (1,168,509)	$ (5,542,142)
Per share information:
Net loss per share, basic	$ (0.31)	$ (17.62)
Net loss per share, diluted	$ (0.31)	$ (17.62)
Weighted average shares outstanding, basic	3,797,753	314,472
Weighted average shares outstanding, diluted	3,797,753	314,472

SONN Balance Sheet

2023-12-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash	$ 3,021,392	$ 2,274,259
Prepaid expenses and other current assets	1,408,280	1,677,396
Incentive tax receivable	194,111	786,574
Total current assets	4,623,783	4,738,229
Property and equipment, net	30,155	33,366
Operating lease right-of-use asset	176,926	193,689
Deferred offering costs	15,000	49,988
Other assets	491,862	414,206
Total assets	5,337,726	5,429,478
Current liabilities:
Accounts payable	1,655,390	2,201,999
Accrued expenses and other current liabilities	923,191	3,230,922
Current portion of operating lease liability	75,730	73,048
Deferred income		18,626
Total current liabilities	2,654,311	5,524,595
Operating lease liability, net of current portion	110,956	130,863
Total liabilities	2,765,267	5,655,458
Commitments and contingencies (Note 4)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,069,516 and 1,750,426 issued and outstanding at December 31, 2023 and September 30, 2023, respectively	307	175
Additional paid-in capital	113,984,414	110,017,598
Accumulated deficit	(111,412,262)	(110,243,753)
Total stockholders’ equity (deficit)	2,572,459	(225,980)
Total liabilities and stockholders’ equity (deficit)	$ 5,337,726	$ 5,429,478

About Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

CEO	Dr. Pankaj Mohan Ph.D.
WEBSITE	sonnetbio.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Sonnet BioTherapeutics Holdings Inc? What does SONN stand for in stocks?

SONN is the stock ticker symbol of Sonnet BioTherapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sonnet BioTherapeutics Holdings Inc (SONN)?

As of Tue Apr 30 2024, market cap of Sonnet BioTherapeutics Holdings Inc is 5.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SONN stock?

You can check SONN's fair value in chart for subscribers.

What is the fair value of SONN stock?

You can check SONN's fair value in chart for subscribers. The fair value of Sonnet BioTherapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sonnet BioTherapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SONN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sonnet BioTherapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether SONN is over valued or under valued. Whether Sonnet BioTherapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Sonnet BioTherapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SONN.

What is Sonnet BioTherapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, SONN's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 42.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SONN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sonnet BioTherapeutics Holdings Inc's stock?

In the past 10 years, Sonnet BioTherapeutics Holdings Inc has provided -0.773 (multiply by 100 for percentage) rate of return.